Plus   Neg

Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for DUPIXENT (dupilumab) for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies. DUPIXENT is a human monoclonal antibody designed to specifically inhibit signaling of two key proteins, IL-4 and IL-13, which are believed to be important contributors of the persistent underlying inflammation in atopic dermatitis, and certain other allergic or atopic diseases.

Dupixent is being jointly developed by Regeneron and Sanofi under a global collaboration agreement, and will be commercialized in Japan by Sanofi.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Saudi Arabia's oil major Aramco is reportedly planning to list its much hyped initial public offering on the Saudi stock market, Tadawu only. Earlier, the Dhahran-based Saudi Arabian national petroleum company was planning for a wider international listing. Following a disastrous week of public-relations fiascoes involving transportation of pets, United Airlines said Tuesday it is suspending its Petsafe program with immediate effect. PetSafe is United Airlines' specially designed program for transporting animals that are not eligible to travel in the aircraft cabin. The program offers airport-to-airport travel for animals to nearly 300 destinations. Chipotle Mexican Grill, the Mexican food-chain that continues to struggle from its food-borne illness scandal, on Tuesday said it has appointed Chris Brandt as its new Chief Marketing Officer to replace Mark Crumpacker, who resigned last week. Most recently, Brandt worked at Bloomin' Brands, where...
comments powered by Disqus
Follow RTT